2023 annual financial data
Tvardi Therapeutics 2023 Operating margin
Tvardi Therapeutics 2023 operating margin with verified reported values.
Direct answer
Operating margin was -579.43%.
Operating income was -121,495,000 USD and net income was -118,513,000 USD.
Operating cash flow was -21,040,000 USD.
Get free Tvardi Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 20,968,000 USD
- Operating income
- -121,495,000 USD
- Net income
- -118,513,000 USD
- Operating cash flow
- -21,040,000 USD